1944 related articles for article (PubMed ID: 8823492)
21. In vitro and in vivo pharmacological characterizations of the antitumor properties of two new olivacine derivatives, S16020-2 and S30972-1.
Malonne H; Farinelle S; Decaestecker C; Gordower L; Fontaine J; Chaminade F; Saucier JM; Atassi G; Kiss R
Clin Cancer Res; 2000 Sep; 6(9):3774-82. PubMed ID: 10999772
[TBL] [Abstract][Full Text] [Related]
22. Activity of SC33428, a novel bishydrazone-bridged derivative of 4-demethoxydaunorubicin, against experimental tumors in mice.
Dawson KM
Cancer Res; 1983 Jun; 43(6):2880-3. PubMed ID: 6573953
[TBL] [Abstract][Full Text] [Related]
23. Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers.
Tsuruo T; Iida H; Nojiri M; Tsukagoshi S; Sakurai Y
Cancer Res; 1983 Jun; 43(6):2905-10. PubMed ID: 6850602
[TBL] [Abstract][Full Text] [Related]
24. Tyrosine and phenylalanine restriction sensitizes adriamycin-resistant P388 leukemia cells to adriamycin.
Elstad CA; Thrall BD; Raha G; Meadows GG
Nutr Cancer; 1996; 25(1):47-60. PubMed ID: 8837861
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy with cytochalasin congeners in vitro and in vivo against murine models.
Trendowski M; Mitchell JM; Corsette CM; Acquafondata C; Fondy TP
Invest New Drugs; 2015 Apr; 33(2):290-9. PubMed ID: 25563824
[TBL] [Abstract][Full Text] [Related]
26. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
27. Preclinical antitumor activity of an alpha-picoline derivative, penclomedine (NSC 338720), on human and murine tumors.
Plowman J; Harrison SD; Dykes DJ; Paull KD; Narayanan VL; Tobol HK; Martin J; Griswold DP
Cancer Res; 1989 Apr; 49(8):1909-15. PubMed ID: 2702634
[TBL] [Abstract][Full Text] [Related]
28. Reversal of multidrug resistance by a novel quinoline derivative, MS-209.
Sato W; Fukazawa N; Nakanishi O; Baba M; Suzuki T; Yano O; Naito M; Tsuruo T
Cancer Chemother Pharmacol; 1995; 35(4):271-7. PubMed ID: 7828268
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of DMP 840: a novel bis-naphthalimide cytotoxic agent with human solid tumor xenograft selectivity.
McRipley RJ; Burns-Horwitz PE; Czerniak PM; Diamond RJ; Diamond MA; Miller JL; Page RJ; Dexter DL; Chen SF; Sun JH
Cancer Res; 1994 Jan; 54(1):159-64. PubMed ID: 8261436
[TBL] [Abstract][Full Text] [Related]
30. Antitumor activity of a new fluoropyrimidine derivative, 5'-deoxy-5-fluorouridine, against murine and human experimental tumors.
Fujimoto S; Wang Y; Inoue K; Ogawa M
Jpn J Cancer Res; 1985 Jul; 76(7):644-50. PubMed ID: 3161854
[TBL] [Abstract][Full Text] [Related]
31. Activity of a novel anthracenedione, 1,4-dihydroxy-5,8-bis(((2-[(2-hydroxyethyl)amino]ethyl)amino])-9,10-anthracenedione dihydrochloride, against experimental tumors in mice.
Wallace RE; Murdock KC; Angier RB; Durr FE
Cancer Res; 1979 May; 39(5):1570-4. PubMed ID: 427798
[TBL] [Abstract][Full Text] [Related]
32. MX2, a morpholino anthracycline, as a new antitumor agent against drug-sensitive and multidrug-resistant human and murine tumor cells.
Watanabe M; Komeshima N; Nakajima S; Tsuruo T
Cancer Res; 1988 Dec; 48(23):6653-7. PubMed ID: 3180075
[TBL] [Abstract][Full Text] [Related]
33. Schedule dependence, activity against natural metastases, and cross-resistance of pyrazine diazohydroxide (sodium salt, NSC 361456) in preclinical models in vivo.
Harrison SD; Plowman J; Dykes DJ; Waud WR; Griswold DP
Cancer Chemother Pharmacol; 1990; 25(6):425-9. PubMed ID: 2311170
[TBL] [Abstract][Full Text] [Related]
34. Antitumor activity of 2-chloroethyl (methylsulfonyl)methanesulfonate (clomesone, NSC 33847) against selected tumor systems in mice.
Dykes DJ; Waud WR; Harrison SD; Laster WR; Griswold DP; Shealy YF; Montgomery JA
Cancer Res; 1989 Mar; 49(5):1182-6. PubMed ID: 2537144
[TBL] [Abstract][Full Text] [Related]
35. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A.
Quintieri L; Rosato A; Napoli E; Sola F; Geroni C; Floreani M; Zanovello P
Cancer Res; 2000 Jun; 60(12):3232-8. PubMed ID: 10866316
[TBL] [Abstract][Full Text] [Related]
36. In vivo activity on murine tumors of a novel antitumor compound, N-beta-dimethylaminoethyl 9-carboxy-5-hydroxy-10-methoxybenzo[a]phenazine-6-carboxamide sodium salt (NC-190).
Nakaike S; Yamagishi T; Samata K; Nishida K; Inazuki K; Ichihara T; Migita Y; Otomo S; Aihara H; Tsukagoshi S
Cancer Chemother Pharmacol; 1989; 23(3):135-9. PubMed ID: 2924370
[TBL] [Abstract][Full Text] [Related]
37. Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer.
Utsugi T; Shibata J; Sugimoto Y; Aoyagi K; Wierzba K; Kobunai T; Terada T; Oh-hara T; Tsuruo T; Yamada Y
Cancer Res; 1996 Jun; 56(12):2809-14. PubMed ID: 8665518
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and antitumor activity of 9-acyloxyellipticines.
Harada N; Ozaki K; Oda K; Nakanishi N; Ohashi M; Hashiyama T; Tsujihara K
Chem Pharm Bull (Tokyo); 1997 Jul; 45(7):1156-62. PubMed ID: 9246749
[TBL] [Abstract][Full Text] [Related]
39. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.
Bissery MC; Vrignaud P; Lavelle F; Chabot GG
Anticancer Drugs; 1996 Jun; 7(4):437-60. PubMed ID: 8826613
[TBL] [Abstract][Full Text] [Related]
40. Preclinical antitumour activity of F 11782, a novel dual catalytic inhibitor of topoisomerases.
Kruczynski A; Etiévant C; Perrin D; Imbert T; Colpaert F; Hill BT
Br J Cancer; 2000 Dec; 83(11):1516-24. PubMed ID: 11076662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
